GlassScriptPhysician profile
Jena M Thomas
NPI 1831673755
$2,414.14
in general payments reported to CMS, 2019-2025
20 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $435 · 2023: $697 · 2024: $412 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $422.94 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $321.52 | 2021-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $304.61 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $205.61 | 2021-2023 | Lybalvi |
| Corium, LLC | $195.98 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $177.01 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $98.75 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $98.22 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.61 | 2022-2023 | Caplyta |
| Indivior INC. | $78.64 | 2021-2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $75.12 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $70.58 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $64.70 | 2023-2024 | Auvelity |
| Tempus Ai, INC | $50.30 | 2024-2025 | Tempus Pixel |
| Biogen, INC. | $43.41 | 2025 | Zurzuvae |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $29.67 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.05 | 2023 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $20.45 | 2025 | Cobenfy |
| Tris Pharma INC | $19.95 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $18.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jena Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.